UPDATE: OraSure Receives FDA Approval of OraQuick In-Home HIV Test
OraSure Technologies, Inc. (Nasdaq: OSUR) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's OraQuick® In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market – making it the first and only rapid OTC HIV test approved in the U.S. The OraQuick® In-Home HIV Test can detect antibodies to both HIV-1 and HIV-2 with an oral swab, providing a confidential in-home testing option with results in as little as 20 minutes. It is the first rapid diagnostic test for any infectious disease that has been approved by the FDA for sale over the counter.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.